Siemens Sets 2027 Vote for Healthineers Spin-Off as Investors Weigh Patience

Siemens has finalized the timeline for its most significant corporate overhaul in recent years, setting a shareholder vote on the spin-off of its medical technology unit, Siemens Healthineers, for February 2027. The move solidifies a strategic pivot toward pure-play technology, though the extended timeline is testing investor patience.

The conglomerate plans to execute a direct spin-off under German transformation law. Siemens currently holds approximately 67% of Healthineers and intends to distribute about 30% of those shares directly to its own shareholders. This will reduce Siemens’s stake to a minority holding, effectively relinquishing its majority control. Shareholders will see the new Healthineers stock deposited directly into their accounts, pending a crucial tax ruling from financial authorities to ensure the transaction remains tax-neutral.

Strategic Refocus and Market Reactions

This separation is a cornerstone of Siemens’s strategy to sharpen its focus on its core technology businesses. Management is steering the company toward automation, industrial digitalization, and smart building infrastructure, areas it views as its future growth engines. The plan, first announced in November 2025, is now officially on the calendar, albeit later than some market observers had hoped.

Should investors sell immediately? Or is it worth buying Siemens?

The market’s reaction to the confirmed schedule has been muted. Siemens shares traded around 240 euros in XETRA trading, having gained roughly 11% over the past month and recently moving above the closely watched 200-day moving average to close at 239.60 euros on Friday. Analysts are divided on the pace of the separation. RBC Capital Markets confirmed its 270-euro price target for Siemens, with analyst Mark Fielding acknowledging the slow tempo as an expected risk given regulatory complexities. Conversely, Goldman Sachs analyst Daniela Costa cut her target to 235 euros, citing a weak reporting season ahead for European capital goods and soft order intake in the first quarter.

Supporting Moves and Upcoming Test

Alongside the restructuring, Siemens is actively supporting its share price through a buyback program. Since February 2024, the company has repurchased over 25 million of its own shares, reducing the free float by more than three percentage points. This corporate action coincides with notable institutional positioning, as French asset manager Amundi recently crossed the reporting threshold to hold 3.18% of Siemens’s voting rights.

Attention now turns to the upcoming quarterly report. On May 13, 2026, Siemens will release its second-quarter figures, which will serve as a key test of whether the broader industry headwinds highlighted by analysts are materially impacting the Munich-based group. Meanwhile, the spin-off’s progress remains in focus, with Morgan Stanley lowering its price target for Healthineers stock to 41 euros, contributing to slight losses for the subsidiary’s shares at the end of the week.

Ad

Siemens Stock: New Analysis - 18 April

Fresh Siemens information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Siemens analysis...

en | DE0007236101 | SIEMENS | boerse | 69186180 |